Preferential Upregulation of AMOT-p80 Is Associated with YAP-Linked Resistance to 5-Fluorouracil and Oxaliplatin in Colorectal Cancer Cells
Biomolecules · 2026
DOI: 10.3390/biom16060767 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2026. Verfasst von Yeho Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Sungkyunkwan University School of Medicine, 2066 Seobu-ro, Jangan-gu, Suwon 16419, Gyeonggi-do, Republic of Korea. Hauptthemen laut MEDLINE: Fluorouracil, Oxaliplatin, Colorectal Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Resistance to 5-fluorouracil (5-FU) and oxaliplatin (OXA) remains an obstacle in colorectal cancer (CRC) therapy, but the upstream mechanisms enabling adaptive survival remain unclear. Angiomotin (AMOT), a Hippo-YAP regulator, is expressed as two major isoforms, p130 and p80, but the contribution of isoform-specific AMOT regulation to chemoresistance is unknown. RNA-seq of OXA-resistant cells identified AMOT as a candidate determinant, and its isoform-specific regulation and functional relevance were then examined in OXA- and 5-FU-resistant CRC sublines. AMOT-p80 was preferentially upregulated, whereas AMOT-p130 remained largely unchanged. Common AMOT pre-mRNA was elevated, whereas p130-specific pre-mRNA was unchanged, consistent with preferential transcriptional activation favoring the p80 isoform. Functionally, AMOT depletion minimally affected basal viability but significantly sensitized resistant cells to 5-FU or OXA, with increased apoptotic responses. AMOT silencing reduced nuclear YAP and lowered c-Myc and Cyclin D1 protein levels, whereas AMOT-p80 re-expression restored nuclear YAP, with recovery of c-Myc/Cyclin D1 levels and drug tolerance. YAP knockdown attenuated these outputs and blunted the additional effect of AMOT depletion. AMOT-p80 overexpression in parental cells increased c-Myc/Cyclin D1 protein levels and enhanced tolerance to 5-FU and OXA. These findings suggest that preferential AMOT-p80 upregulation is linked to YAP-associated chemoresistant phenotypes in CRC cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Sungkyunkwan University School of Medicine, 2066 Seobu-ro, Jangan-gu, Suwon 16419, Gyeonggi-do, Republic of Korea.
ORCID-Profile: Yeho Kim, Jin-Kyung Hong, Jae-Hyeon Woo, Joo-Ho Shin, Yunjong Lee
Förderung
- National Research Foundation of Korea
Zitieren
APA
Kim, Y., Hong, J. K., Yeom, M., Kim, M. J., Woo, J. H., Shin, J. H., Won, T. H., Lee, Y., & Choi, J. Y. (2026). Preferential Upregulation of AMOT-p80 Is Associated with YAP-Linked Resistance to 5-Fluorouracil and Oxaliplatin in Colorectal Cancer Cells. Biomolecules. https://doi.org/10.3390/biom16060767
Vancouver
Kim Y, Hong JK, Yeom M, Kim MJ, Woo JH, Shin JH, et al. Preferential Upregulation of AMOT-p80 Is Associated with YAP-Linked Resistance to 5-Fluorouracil and Oxaliplatin in Colorectal Cancer Cells. Biomolecules. 2026. doi:10.3390/biom16060767
BibTeX
@article{Kim2026,
author = {Kim, Yeho and Hong, Jin-Kyung and Yeom, Mina and Kim, Min-Ju and Woo, Jae-Hyeon and Shin, Joo-Ho and Won, Tae Hyung and Lee, Yunjong and Choi, Jeong-Yun},
title = {Preferential Upregulation of AMOT-p80 Is Associated with YAP-Linked Resistance to 5-Fluorouracil and Oxaliplatin in Colorectal Cancer Cells},
journal = {Biomolecules},
year = {2026},
doi = {10.3390/biom16060767}
}
EUVIMED